Absci accelerates ABS-201 in alopecia & endometriosis, targets data by 2027, and refocuses pipeline for value.
On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201 strategy to pursue endometriosis as additional ...
22m
Absci Corp (ABSI) Q3 2025 Earnings Call Highlights: Strategic Shifts and Strong Cash Position ...
Absci Corp (ABSI) focuses on advancing ABS-201 trials while seeking partnerships for ABS-101, backed by a robust cash reserve to fund operations into 2028.
TipRanks on MSN
Absci Reports Q3 Results, Focuses on ABS-201
The latest announcement is out from AbSci ( (ABSI) ).
TipRanks on MSN
Absci reports Q3 EPS (20c), consensus (21c)
Reports Q3 revenue $378k, consensus $1.58M. “This quarter marks a pivotal inflection point for Absci (ABSI) as we sharpen our focus on ABS-201, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback